It is with out doubt many including myself anticipated the possibility of early results, lesson learnt. SI and team have a better understanding of the time line than we do.
Why has it taken longer than we have expected ?
I think it possible that it is a combination of many things including trial design . A lot to get done in the first 3 days before enrollment and treatment, any delay in the first 2 days would exclude them from this trial . I would also think that caution would play a part.
I also would not be surprised if we may be testing Remestemcell-L with different manufacturing technology. For example, starting with what we had on hand then going to the new 3D manufacturing capabilities and then possible using fresh to finish the trail. If we are to treat large numbers , this is the type of data that will be required.
Good luck all
- Forums
- ASX - By Stock
- MSB
- Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C, page-230
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B |
Open | High | Low | Value | Volume |
$1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12398 | $1.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.47 | 5440 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 12398 | 1.460 |
2 | 19558 | 1.455 |
5 | 49977 | 1.450 |
5 | 102249 | 1.445 |
2 | 30389 | 1.440 |
Price($) | Vol. | No. |
---|---|---|
1.465 | 5440 | 3 |
1.470 | 22187 | 2 |
1.475 | 84389 | 3 |
1.480 | 118230 | 9 |
1.485 | 96793 | 8 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online